Interferon ( IFN ) – g , Tumor Necrosis Factor – a , Interleukin-6 , and IFN-g Receptor 1 Are the Major Immunological Determinants Associated with Post – Kala Azar Dermal Leishmaniasis

Semiquantitative reverse-transcription polymerase chain reaction was used to analyze intralesional cytokine gene expression in 28 patients with post–kala azar dermal leishmaniasis (PKDL) and 14 patients with kala azar (KA). The data revealed mixed T helper cell type 1 (Th1) and T helper cell type 2 (Th2) responses, as reflecte by elevated expression of interferon (IFN)–g, tumor necrosis factor (TNF)–a, transforming growth factor (TGF)–b, interleukin (IL)–10, IL-6, and IL-4 mRNA, with minimal expression of IFN-g receptor 1 (IFNgR1) mRNA in PKDL lesions, compared with that in normal skin tissue. In comparison with those in KA lesions, mRNA levels for IFN-g, TNF-a, and IL-6 were found to be significantl elevated in PKDL lesions, implying that these cytokines play an important role in PKDL pathogenesis. In the presence of elevated levels of IFN-g and TNF-a, interference with type 1 effector activity in PKDL may be due to minimal expression of the IFN-gR1 gene or the simultaneous presence of elevated levels of IL-10, IL-6, and TGF-b, which have counteracting effects. After treatment, the restoration of IFN-gR1 at both mRNA and protein levels, coupled with down-regulation of counteracting cytokines, may facilitate the action of signals associated with IFN-g, yielding parasite clearance. Therefore, unfavorable clinical evolution in PKDL may not be due to the absence of an intralesional Th1 response but rather may be due to the presence of counteracting cytokines along with the down-modulation of IFN-gR1.

[1]  K. Sardana,et al.  Postkala‐azar dermal leishmaniasis coexisting with borderline tuberculoid leprosy , 2007, The British journal of dermatology.

[2]  Dhiraj Kumar,et al.  Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. , 2006, The Journal of infectious diseases.

[3]  P. Salotra,et al.  Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. , 2006, Clinical immunology.

[4]  M. Kaye,et al.  IN VIVO AND IN VITRO , 2006 .

[5]  Y. Belkaid,et al.  Conditions Influencing the Efficacy of Vaccination with Live Organisms against Leishmania major Infection , 2005, Infection and Immunity.

[6]  Yasmine Belkaid,et al.  Natural regulatory T cells in infectious disease , 2005, Nature Immunology.

[7]  P. Desjeux Leishmaniasis: current situation and new perspectives. , 2004, Comparative immunology, microbiology and infectious diseases.

[8]  J. Blackwell,et al.  Genetics and visceral leishmaniasis in the Sudan: seeking a link. , 2004, Trends in parasitology.

[9]  D.Y. Lee,et al.  Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT‐PCR , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[10]  P. Kaye,et al.  Both Interleukin-4 (IL-4) and IL-4 Receptor α Signaling Contribute to the Development of Hepatic Granulomas with Optimal Antileishmanial Activity , 2003, Infection and Immunity.

[11]  E. N. Miller,et al.  Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1 , 2003, Genes and Immunity.

[12]  P. Das,et al.  Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells , 2003, Annals of tropical medicine and parasitology.

[13]  E. Pugh,et al.  Association between the Tumor Necrosis Factor Locus and the Clinical Outcome of Leishmania chagasi Infection , 2002, Infection and Immunity.

[14]  R. Coffman,et al.  Interleukin-10 (IL-10) in Experimental Visceral Leishmaniasis and IL-10 Receptor Blockade as Immunotherapy , 2002, Infection and Immunity.

[15]  Shyam Sundar,et al.  Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. , 2002, The Lancet. Infectious diseases.

[16]  Y. Belkaid,et al.  The Role of Interleukin (IL)-10 in the Persistence of Leishmania major in the Skin after Healing and the Therapeutic Potential of Anti–IL-10 Receptor Antibody for Sterile Cure , 2001, The Journal of experimental medicine.

[17]  S. Sundar Drug resistance in Indian visceral leishmaniasis , 2001, Tropical medicine & international health : TM & IH.

[18]  F. Powrie,et al.  Regulatory T cells in the control of immune pathology , 2001, Nature Immunology.

[19]  H. Nakhasi,et al.  Development of a Species-Specific PCR Assay for Detection of Leishmania donovani in Clinical Samples from Patients with Kala-Azar and Post-Kala-Azar Dermal Leishmaniasis , 2001, Journal of Clinical Microbiology.

[20]  M. Roncarolo,et al.  Differentiation of T Regulatory Cells by Immature Dendritic Cells , 2001, The Journal of experimental medicine.

[21]  B. Lell,et al.  Plasma interleukin-10:Tumor necrosis factor (TNF)-alpha ratio is associated with TNF promoter variants and predicts malarial complications. , 2000, The Journal of infectious diseases.

[22]  H. Murray,et al.  Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. , 2000, The Journal of infectious diseases.

[23]  J. Wang,et al.  Consideration of cytokines as therapeutics agents or targets. , 2000, Current pharmaceutical design.

[24]  P. Marrack,et al.  Activation-Induced Inhibition of Interleukin 6–Mediated T Cell Survival and Signal Transducer and Activator of Transcription 1 Signaling , 2000, The Journal of experimental medicine.

[25]  M. Ray,et al.  Inhibition of interferon-gamma signaling by Leishmania donovani. , 2000, The Journal of infectious diseases.

[26]  T. Theander,et al.  Immunopathology of post kala‐azar dermal leishmaniasis (PKDL): T‐cell phenotypes and cytokine profile , 1999, The Journal of pathology.

[27]  A. Allione,et al.  Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. , 1999, Journal of immunology.

[28]  T. Theander,et al.  Leishmania‐specific T cells expressing interferon‐gamma (IFN‐γ) and IL‐10 upon activation are expanded in individuals cured of visceral leishmaniasis , 1999, Clinical and experimental immunology.

[29]  T. Theander,et al.  T-cell response in human leishmaniasis. , 1999, Immunology letters.

[30]  P. Salotra,et al.  Western blot analysis of humoral immune response to Leishmania donovani antigens in patients with post-kala-azar dermal leishmaniasis. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[31]  F. Handjani,et al.  Post-kala-azar dermal leishmaniasis. , 1998, European journal of dermatology : EJD.

[32]  K. Dellagi,et al.  Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. , 1998, The Journal of infectious diseases.

[33]  S. Sundar,et al.  Splenic cytokine responses in Indian kala-azar before and after treatment. , 1998, The Journal of infectious diseases.

[34]  E. Zijlstra,et al.  Post kala-azar ocular leishmaniasis. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[35]  T. Theander,et al.  High levels of plasma IL‐10 and expression of IL‐10 by keratinocytes during visceral leishmaniasis predict subsequent development of post‐kala‐azar dermal leishmaniasis , 1998, Clinical and experimental immunology.

[36]  H. Noyes,et al.  Leishmania Chagasi: Genotypically Similar Parasites from Honduras Cause Both Visceral and Cutaneous Leishmaniasis in Humans , 2022 .

[37]  G. Stassi,et al.  In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. , 1995, Cytokine.

[38]  M. Aguet,et al.  Development of antimalaria immunity in mice lacking IFN-gamma receptor. , 1995, Journal of immunology.

[39]  S. Huang,et al.  Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response , 1995, The Journal of experimental medicine.

[40]  V. Ramesh,et al.  Post‐kala‐azar dermal leishmaniasis , 1993, The Australasian journal of dermatology.

[41]  Darnell,et al.  Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis , 1994, Infection and immunity.

[42]  R. de Waal Malefyt,et al.  Expression cloning and characterization of a human IL-10 receptor. , 1994, Journal of immunology.

[43]  Y. Liu,et al.  A receptor for interleukin 10 is related to interferon receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Sobel,et al.  IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. , 1993, Journal of immunology.

[45]  Mohamed,et al.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections. , 1993, The Journal of clinical investigation.

[46]  Wynn,et al.  In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. , 1993, The Journal of clinical investigation.

[47]  J Sanceau,et al.  Tumor necrosis factor-alpha and IL-6 up-regulate IFN-gamma receptor gene expression in human monocytic THP-1 cells by transcriptional and post-transcriptional mechanisms. , 1992, Journal of immunology.

[48]  S. Reed,et al.  Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. , 1992, Science.

[49]  E. Zijlstra,et al.  Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. , 1992, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[50]  F. Liew,et al.  Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. , 1990, Journal of immunology.

[51]  Y. Leng A review of kala-azar in China from 1949 to 1959. , 1982, Transactions of the Royal Society of Tropical Medicine and Hygiene.